This review discusses bidirectional links between NAFLD and type 2 diabetes, recommends MAFLD nomenclature, and details screening with noninvasive tests/imaging for advanced fibrosis. Outlines lifestyle, glucose-lowering drugs, and metabolic surgery, noting extra-hepatic risks and medication considerations.